Dehydration News and Research

Latest Dehydration News and Research

Positive results from Glenmark's crofelemer Phase 2 study in acute watery diarrhea

Napo Pharmaceuticals, Inc. is pleased to announce the positive results of a successfully completed Phase 2 study of crofelemer for the treatment of hospitalized adult patients with mild to moderate acute watery diarrhea conducted by its partner Glenmark Pharmaceuticals Ltd..

14 Feb 2011

Key advance in development of fast, simple test for detection of cholera

With cholera on the rampage in Haiti and almost 40 other countries, scientists are reporting the development of a key advance that could provide a fast, simple test to detect the toxin that causes the disease. The report appears in ACS' journal Bioconjugate Chemistry. Cholera affects more than 200,000 people annually, mainly in developing countries, and causes about 5,000 deaths. Many involve infants, children, and the elderly.

10 Feb 2011

AJN: Nurses and physicians lack knowledge about human trafficking

A report, published in the February issue of the American Journal of Nursing, underscores nurse and physicians' lack of knowledge about the indicators of human trafficking when they encounter a patient who is a victim of trafficking.

8 Feb 2011

Genentech's OCEANS Phase III study of Avastin in platinum-sensitive ovarian cancer meets primary endpoint

Genentech, a member of the Roche Group, announced today that OCEANS, a Phase III study evaluating Avastin® (bevacizumab) in combination with chemotherapy (carboplatin and gemcitabine) followed by continued use of Avastin alone until disease progression in women with previously treated (recurrent), platinum-sensitive ovarian cancer, met its primary endpoint.

8 Feb 2011

Phase II results of VELCADE in patients with aggressive lymphoma published in Journal of Clinical Oncology

Millennium: The Takeda Oncology Company today announced that Phase II results of a clinical trial examining VELCADE (bortezomib) in patients with previously untreated aggressive lymphoma were published in the Journal of Clinical Oncology.

5 Feb 2011

Tips for women to ensure a healthy heart and a healthy vacation

Henrico County based Mondial Assistance, the largest travel insurance provider in the world, and the American Heart Association's (AHA) Mid-Atlantic chapter are teaming up for the 2011 Go Red for Women campaign and as part of the effort are offering these tips for women to ensure a healthy heart and a healthy vacation in 2011. Mondial Assistance is a "Healthy Lifestyle" Partner for this year's campaign.

5 Feb 2011

CVT more common than previously thought, disproportionally affects pregnant women

A rare and often underreported form of stroke that involves veins instead of arteries is more common than previously thought, according to the American Heart Association's first scientific statement on diagnosing and managing cerebral venous thrombosis (CVT).

4 Feb 2011

GATTEX Phase 3 pivotal study reaches primary efficacy endpoint of reducing PN in patients with SBS

NPS Pharmaceuticals, a specialty pharmaceutical company developing innovative therapeutics for rare gastrointestinal and endocrine disorders, today announced that its Phase 3 pivotal study of GATTEX met the primary efficacy endpoint of reducing parenteral nutrition dependence in patients with adult short bowel syndrome.

31 Jan 2011

Extreme morning sickness drug comes at a price

Women, who suffer from an extreme form of morning sickness called hyperemesis gravidarum (HG), are shelling out $7,000 for a drug not yet approved for use by expectant mums because they are desperate to control their illness. HG leads to severe nausea, dehydration and fatigue and may require hospitalization. It affects up to 3 per cent of pregnant women - about 9,000 per year in Australia. It may lead to termination of the pregnancy.

31 Jan 2011

FOLOTYN Phase 2 peripheral T-cell lymphoma study results published in Journal of Clinical Oncology

Allos Therapeutics, Inc. today announced that the Journal of Clinical Oncology has published data from the Company's pivotal Phase 2 PROPEL study demonstrating clinical activity of FOLOTYN® (pralatrexate injection) in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).

20 Jan 2011

Living at higher altitudes may increase risk for suicide

Twenty years of mortality data from counties across the United States led to the striking discovery that living at higher altitudes may be a risk factor for suicide, according to a provocative study published online ahead of print in High Altitude Medicine & Biology, a peer-reviewed journal published by Mary Ann Liebert, Inc. The article is attached.

14 Jan 2011

FDA accepts Merck's JANUMET extended-release formulation NDA for type 2 diabetes

Merck today announced that the New Drug Application (NDA) for the Company's investigational extended-release formulation of JANUMET for type 2 diabetes has been accepted for standard review by the U.S. Food and Drug Administration (FDA). The Company is also moving forward as planned with regulatory filings in countries outside the United States.

12 Jan 2011

Haiti teen to undergo open-heart surgery at Montefiore

Mahalia Desruisseaux, M.D., assistant professor of pathology and of medicine at Albert Einstein College of Medicine of Yeshiva University who had traveled to Haiti to assist in the relief effort, identified a serious heart condition. Now, one year later, Ms. Ajuste will undergo open-heart surgery at Montefiore, The University Hospital and Academic Medical Center for Einstein, to correct the defect.

11 Jan 2011

OraSure to introduce QuickFlu test for detection of type A and type B influenza

OraSure Technologies, announced today the impending launch of the OraSure QuickFlu Rapid Flu A+B Test, a U.S. Food and Drug and Administration approved in vitro rapid qualitative test for the detection of influenza type A and type B, including H1N1 viral infections.

11 Jan 2011

NPS completes treatment phase in GATTEX Phase 3 registration study in short bowel syndrome

NPS Pharmaceuticals, Inc. a specialty pharmaceutical company developing innovative therapeutics for rare gastrointestinal and endocrine disorders, today announced the completion of the 24-week treatment phase of the company's Phase 3 registration study of GATTEX® (teduglutide).

11 Jan 2011

Shionogi brings KAPVAY ADHD drug to the U.S market

Shionogi Inc., the U.S.-based group company of Shionogi & Co., Ltd., today announced a true milestone as it marks the first commercial availability for the non-central nervous system stimulant medication KAPVAY™, an extended-release oral formulation of clonidine for Attention Deficit Hyperactivity Disorder (ADHD) in children and adolescents.

10 Jan 2011

Tips for surviving a bout with 'stomach flu'

A post-holiday crush of patients are crowding into area physician offices and hospital emergency rooms as individuals of all ages suddenly find themselves laid low by a highly contagious and quick-striking virus.

10 Jan 2011

FDA approved KOMBIGLYZE XR for type 2 diabetes mellitus now available in pharmacies

Bristol-Myers Squibb Company, and AstraZeneca today announced that KOMBIGLYZE™ XR (saxagliptin and metformin HCl extended-release), approved by the U.S. Food and Drug Administration (FDA) on November 5, 2010, is now available by prescription in pharmacies across the United States.

7 Jan 2011

Sugared-sweetened beverages eliminated from Nationwide Children's Hospital campus

According to the American Academy of Pediatrics, sweetened drinks are the primary source of added sugar in the daily diet of children. Each 12-ounce serving of a carbonated, sweetened soft drink contains the equivalent of 10 teaspoons of sugar and 150 calories. A child who consumes one can of regular soda needs to walk 45 minutes just to burn it off.

5 Jan 2011

GLUMETZA tablets are now available to wholesalers and physicians

Santarus, and Depomed, today announced that supply of GLUMETZA® 500 mg to wholesalers and retailers has resumed. GLUMETZA is a once-daily, extended release formulation of metformin and is approved for use in adults with type 2 diabetes mellitus.

5 Jan 2011

Dehydration News and Research

Latest Dehydration News and Research

Positive results from Glenmark's crofelemer Phase 2 study in acute watery diarrhea

Key advance in development of fast, simple test for detection of cholera

AJN: Nurses and physicians lack knowledge about human trafficking

Genentech's OCEANS Phase III study of Avastin in platinum-sensitive ovarian cancer meets primary endpoint

Phase II results of VELCADE in patients with aggressive lymphoma published in Journal of Clinical Oncology

Tips for women to ensure a healthy heart and a healthy vacation

CVT more common than previously thought, disproportionally affects pregnant women

GATTEX Phase 3 pivotal study reaches primary efficacy endpoint of reducing PN in patients with SBS

Extreme morning sickness drug comes at a price

FOLOTYN Phase 2 peripheral T-cell lymphoma study results published in Journal of Clinical Oncology

Living at higher altitudes may increase risk for suicide

FDA accepts Merck's JANUMET extended-release formulation NDA for type 2 diabetes

Haiti teen to undergo open-heart surgery at Montefiore

OraSure to introduce QuickFlu test for detection of type A and type B influenza

NPS completes treatment phase in GATTEX Phase 3 registration study in short bowel syndrome

Shionogi brings KAPVAY ADHD drug to the U.S market

Tips for surviving a bout with 'stomach flu'

FDA approved KOMBIGLYZE XR for type 2 diabetes mellitus now available in pharmacies

Sugared-sweetened beverages eliminated from Nationwide Children's Hospital campus

GLUMETZA tablets are now available to wholesalers and physicians

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Dehydration News and Research

Latest Dehydration News and Research

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Newsletters you may be interested in